Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariel Lopez-Chavez

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Molecular Cancer|April 8, 2011
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivinRonan J Kelly, Ariel Lopez-Chavez, Deborah Citrin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysisAriel Lopez-Chavez, Todd Young, Sophie Fages, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2012
Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 yearsNicola M Neary, Ariel Lopez-Chavez, Brent S Abel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumorsGiuseppe Giaccone, Arun Rajan, Arlene Berman, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLCDavid E Gerber, Paul Swanson, Ariel Lopez-Chavez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibRonan J Kelly, Arun Rajan, Jeremy Force, et al.
Journal of Global Oncology|July 19, 2017
<i>EGFR</i> Mutations in Latinos From the United States and Latin AmericaAriel Lopez-Chavez, Anish Thomas, Moses O Evbuomwan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Molecular Cancer|April 8, 2011
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivinRonan J Kelly, Ariel Lopez-Chavez, Deborah Citrin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysisAriel Lopez-Chavez, Todd Young, Sophie Fages, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2012
Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 yearsNicola M Neary, Ariel Lopez-Chavez, Brent S Abel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumorsGiuseppe Giaccone, Arun Rajan, Arlene Berman, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLCDavid E Gerber, Paul Swanson, Ariel Lopez-Chavez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibRonan J Kelly, Arun Rajan, Jeremy Force, et al.
Journal of Global Oncology|July 19, 2017
<i>EGFR</i> Mutations in Latinos From the United States and Latin AmericaAriel Lopez-Chavez, Anish Thomas, Moses O Evbuomwan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
Pageof 3